Additional data on first non-invasive medical device cleared by the FDA for OCD demonstrated that 73% responded positively to Deep TMS, anddurability of therapeutic effect was shown
Results to be Utilized in Companys Efforts to Secure Reimbursement in OCD
CRESSKILL, N.J. and JERUSALEM, Nov. 11, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced, non-invasive treatment of brain disorders, today announced the publication of new positive data from a post-marketing study at 22 twenty-two clinical sites patients suffering from obsessive-compulsive disorder (OCD) in the Journal of Psychiatric Research.
The patients were treated with BrainsWays proprietary H7-coil deep transcranial magnetic stimulation (Deep TMS) system, the first non-invasive medical device cleared by the U.S. Food and Drug Administration (FDA) for OCD. Response to treatment was defined as at least a 30% reduction in the Yale Brown Obsessive Compulsive Scale (Y-BOCS) score.The data showed that 58% of those who completed the full 29-session course of therapy achieved response. In addition, 73% of patients, including those who did and did not complete the full course of therapy, demonstrated response at least once prior to the conclusion of treatment. Furthermore, a secondary endpoint of the study showed that 52% of patients demonstrated sustained response for at least one month following treatment, thereby showing that the therapeutic effect from Deep TMS can be maintained for weeks.
It is gratifying to see the real-world utility and efficacy of Deep TMS for OCD under clinical conditions, stated Aron Tendler, M.D., Chief Medical Officer of BrainsWay. This important study involved 219 patients at 22 centers across the U.S., and we believe these compelling results are indicative of the benefit this innovative technology can have on patients within a practical treatment setting.
We are thrilled with the results of this post-marketing study and continue to view Deep TMS as an important treatment option for patients suffering from OCD, added Christopher von Jako, Ph.D., President and Chief Executive Officer of BrainsWay. We view the publication of these data in the prestigious Journal of Psychiatric Research as further validation of BrainsWays leadership position in TMS. Importantly, we intend to leverage these compelling results with payors in our efforts to secure reimbursement for Deep TMS in OCD.
OCD is a chronic and disabling disorder that affects about 2.3% of the U.S. population in their lifetime, or an estimated 1.2% of adults per year. The BrainsWay Deep TMS system provides patients suffering from this hard-to-treat disease with hope through a non-invasive treatment option that augments existing OCD therapeutic approaches, such as medication, psychotherapy and cognitive-behavioral therapy (CBT).
BrainsWay received De Novo clearance for the treatment of OCD from the FDA in 2018, following positive results from a randomized, placebo-controlled multicenter clinical trial.
More About the Study
BrainsWay collected real-world clinical treatment data from 219 patients as part of an ongoing post-marketing study. OCD patients were treated with BrainsWays H7 Deep TMS coil as an adjunct to other forms of treatment, and clinical outcomes were assessed using the Y-BOCS score, the gold standard in the field. Prior to each treatment session, patients underwent 3-5 minutes of individualized symptom provocation to activate their OCD circuitry. The primary endpoint was response at 29 treatment sessions, which was the same protocol used in BrainsWays previous pivotal multicenter study which led to FDA clearance. No significant adverse events relating to the treatment were reported.
More About OCD
More than 2.5 million adults in the United States suffer from OCD every year. It is a chronic psychiatric illness characterized by a pattern of obsessive thoughts and compulsive repetitive behaviors, which has a significantly destructive effect on patients day-to-day activities. Current treatment options include high dosages of SRI antidepressant medications (Clomipramine, Fluoxetine, Sertraline, Paroxetine and Fluvoxamine), a form of CBT called exposure and response prevention (ERP), or a combination of these treatment options. OCD is very difficult to treat since many patients do not respond or tolerate medications and ERP. OCD is usually comorbid with other conditions (such as depression or bipolar disorders), making the patient effectively treatment resistant and increasing the illness and treatment burden. As many as 1 in 2 OCD patients have suicidal thoughts, 1 in 4 will attempt suicide in their lifetime, and the risk of completed suicide is ten times higher with OCD than without.
About BrainsWay
BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Companys proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology. The Company received marketing authorization from the U.S. Food and Drug Administration (FDA) for its products for a variety of patient populations, including in 2013 for patients with major depressive disorder (MDD), in 2018 for patients with obsessive-compulsive disorder (OCD), and in 2020 for patients with smoking addiction. BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders. To learn more, please visit http://www.brainsway.com
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words intends, may, will, plans, expects, anticipates, projects, predicts, estimates, aims, believes, hopes, potential or similar words. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Moreover, the data in this press release results from a real-world post marketing study of different patient groups treated under disparate conditions. By its very nature, this data is not blinded, the results as presented involve extrapolations from different data sets without necessarily distinguishing between primary and secondary endpoints, and the data was not reviewed by the US Food and Drug Administration and could be subject to different statistical analyses which could impact the results as expressed herein. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Companys anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Companys intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, and the effect of the global COVID-19 health pandemic on our business and continued uncertainty and market impact relating thereto.
Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading Risk Factors in the Companys filings with the U.S. Securities and Exchange Commission.
Contacts:
BrainsWay: Judy HuberSVP and Chief Financial OfficerJudy.huber@brainsway.com
Investors:Bob YedidLifeSci Advisors646-597-6989Bob@LifeSciAdvisors.com
Read more here:
- Despite currently being unprofitable, EDAP TMS (NASDAQ:EDAP) has delivered a 52% return to shareholders over 5 years - Simply Wall St - April 18th, 2024 [April 18th, 2024]
- BrainsWay Expands Deep TMS Access in Israel Following Significant Increase in Reimbursement Rates - GlobeNewswire - April 18th, 2024 [April 18th, 2024]
- Mastery Logistics Systems partners with Transflo to integrate Workflow AI with MasterMind TMS to deliver a ... - Business Wire - April 18th, 2024 [April 18th, 2024]
- New form of magnetic brain stimulation spells hope for patients with treatment-resistant depression - The Straits Times - April 18th, 2024 [April 18th, 2024]
- Port of Oakland's new TMS provides real-time insights for truckers - CCJ - February 5th, 2024 [February 5th, 2024]
- TMS Taps Michelson To Oversee Global Talent Development 01/02/2024 - MediaPost Communications - February 5th, 2024 [February 5th, 2024]
- 11.24% CAGR Growth in Transportation Management Systems (TMS) Market by Solution (on-premise and cloud-based ... - PR Newswire - February 5th, 2024 [February 5th, 2024]
- MileMaker announces partnership with Turvo to bring advanced TMS - TheTrucker.com - The Trucker - February 5th, 2024 [February 5th, 2024]
- Transportation Management Software & Solutions - Who are the Major Players in the Indian Market? - India Shipping News - February 5th, 2024 [February 5th, 2024]
- Neural effects of TMS trains on the human prefrontal cortex | Scientific Reports - Nature.com - December 25th, 2023 [December 25th, 2023]
- What to know about TMS and how it can treat mental health issues - News3LV - December 25th, 2023 [December 25th, 2023]
- Neuronetics lands FDA clearance for TMS therapy accessory - Medical Device Network - December 25th, 2023 [December 25th, 2023]
- Neurobiological mechanisms of ECT and TMS treatment in ... - BMC Psychiatry - October 31st, 2023 [October 31st, 2023]
- Mishimoto Partners with Redwood Logistics for Seamless TMS ... - Supply Chain Dive - October 31st, 2023 [October 31st, 2023]
- 3 benefits of integrating WMS and TMS software - TechTarget - October 31st, 2023 [October 31st, 2023]
- Trinium and BlueCargo join forces to increase resiliency and agility ... - American Journal of Transportation - October 31st, 2023 [October 31st, 2023]
- Psychiatrist Convicted of Billing Medicare and Private Insurance ... - Department of Justice - October 31st, 2023 [October 31st, 2023]
- FreightPOP TMS Application Earns Acumatica Certification - PR Web - October 31st, 2023 [October 31st, 2023]
- AML RightSource Offers Support for Transaction Monitoring System Selection and Integration - Global Banking And Finance Review - October 31st, 2023 [October 31st, 2023]
- TMS therapy: The cloud hanging over me was gone - WellSpan Health - May 18th, 2023 [May 18th, 2023]
- Depression Relief: Brain Signal Reversal by Magnetic Pulses - Neuroscience News - May 18th, 2023 [May 18th, 2023]
- HWS CENTER LAUNCHES TMS THERAPY, BRINGING CUTTING-EDGE MENTAL HEALTH TREATMENT TO NEW JERSEY - EIN News - May 18th, 2023 [May 18th, 2023]
- Incoming TMS students take tours of site - Yahoo News - May 18th, 2023 [May 18th, 2023]
- Passion Drives TMS Titanium's Todd Harrison - Drag Illustrated - May 18th, 2023 [May 18th, 2023]
- EDAP TMS S A : Positive results from two studies reconfirm safety ... - Marketscreener.com - May 18th, 2023 [May 18th, 2023]
- Shiba Inu (SHIB) Whale Purchasing Into The TMS Network (TMSN ... - Analytics Insight - May 18th, 2023 [May 18th, 2023]
- TMS Coils Market 2023 Business Growth and Opportunities with Top ... - Cottonwood Holladay Journal - May 18th, 2023 [May 18th, 2023]
- The Top Cryptos To Buy In 2023 - Arbitrum, Polygon and TMS Network - Analytics Insight - May 18th, 2023 [May 18th, 2023]
- Accelerated delivery of transcranial magnetic stimulation is safe and effective - Newswise - May 18th, 2023 [May 18th, 2023]
- Polygon (MATIC) and Solana (SOL) Drop by 10%, While TMS ... - Crypto Reporter - May 18th, 2023 [May 18th, 2023]
- VeChain (VET) & Curve DAO Token (CRV) Investors Diversify Their ... - Analytics Insight - May 18th, 2023 [May 18th, 2023]
- As Cardano (ADA) Stumbles And Dogecoin (DOGE) Falters, TMS ... - UseTheBitcoin - May 18th, 2023 [May 18th, 2023]
- Nexstim's Quality System and NBS 6 Receive MDR - GlobeNewswire - May 18th, 2023 [May 18th, 2023]
- Uniswap (UNI) and Shiba Inu (SHIB) Underwater as Crypto Looks ... - The Merkle Hash - May 18th, 2023 [May 18th, 2023]
- NeuroStim TMS Celebrates Landmark Achievement, Delivering Over 100,000 TMS Treatments Upon Reaching Five Year Anniversary - Yahoo Finance - May 6th, 2023 [May 6th, 2023]
- Modeling the antidepressant treatment response to transcranial ... - Nature.com - May 6th, 2023 [May 6th, 2023]
- USD Coin (USDC) & Optimism (OP)'s Investors Are Aping Into TMS ... - Analytics Insight - May 6th, 2023 [May 6th, 2023]
- TMS Network (TMSN) Presale Gains 2400%: Optimism (OP) and ... - Analytics Insight - May 6th, 2023 [May 6th, 2023]
- The Best Anime By TMS Entertainment - GameRant - May 6th, 2023 [May 6th, 2023]
- TMS Network (TMSN) Predicted To Pass Shiba Inu (SHIB) And Stacks (STX) In Popularity Within A Year | - Bitcoinist - May 6th, 2023 [May 6th, 2023]
- Towering Over Solana (SOL) and Dogecoin (DOGE), TMS Network (TMSN) Takes the Crown | Bitcoinist.com - Bitcoinist - May 6th, 2023 [May 6th, 2023]
- Market Corrections Push Cardano (ADA) and Polygon (MATIC ... - Analytics Insight - May 6th, 2023 [May 6th, 2023]
- Chainlink vs TMS Network vs TRON : One of them With Deliver ... - The Coin Republic - May 6th, 2023 [May 6th, 2023]
- PCS Software Named a Preferred Partner as Kuebix TMS Sunsets - Benzinga - May 6th, 2023 [May 6th, 2023]
- Could Musk Suit Have Negative Impact on Dogecoin (DOGE) and ... - Crypto Reporter - May 6th, 2023 [May 6th, 2023]
- The Future of Logistics: How Technology is Revolutionizing the ... - Robotics and Automation News - May 6th, 2023 [May 6th, 2023]
- Baru Gold Designated "National Vital Object" and Updates ... - Junior Mining Network - May 6th, 2023 [May 6th, 2023]
- Early Bird offer for TMS Awards - The Maritime Standard - May 6th, 2023 [May 6th, 2023]
- St Helen's Hospital patient says many are 'devastated' by its imminent closure - ABC News - May 6th, 2023 [May 6th, 2023]
- Transcranial Magnetic Stimulation (TMS) | Sibley Memorial Hospital in ... - March 31st, 2023 [March 31st, 2023]
- Psychiatry | Sibley Memorial Hospital in Washington, D.C. - March 31st, 2023 [March 31st, 2023]
- Want To Win Big? Experts Suggest To Choose TMS Network (TMSN) Over Arbitrum (ARB) And Polygon (MATIC) | - Bitcoinist - March 31st, 2023 [March 31st, 2023]
- TMS Network (TMSN) AI Infrastructure Will Give You 100x Returns, Way Better Than SingularityNET (AGIX) And - Bitcoinist - March 31st, 2023 [March 31st, 2023]
- TMS: What It Felt Like for Me I Psych Central - February 20th, 2023 [February 20th, 2023]
- Are we in a recession? Crypto giant Bitcoin and Ethereum stall out while TMS Network makes its mark - FXStreet - February 20th, 2023 [February 20th, 2023]
- Are GameFi coins like SHIB and Decentraland (MANA) as good of a long term investment as TMS Network? - FXStreet - February 20th, 2023 [February 20th, 2023]
- Launch of New Tron (TRX)-powered AI on the Way, Doritos Launches Project on Polygon (MATIC) While TMS Network (TMSN) Brings New Hopes for Brighter... - February 20th, 2023 [February 20th, 2023]
- What is a Transportation Management System? | Oracle - January 31st, 2023 [January 31st, 2023]
- TMS (Transcranial Magnetic Stimulation): What It Is - January 19th, 2023 [January 19th, 2023]
- HC Wainwright Adjusts Price Target on EDAP TMS S.A to $12 From $11, Maintains Buy Rating - Marketscreener.com - November 21st, 2022 [November 21st, 2022]
- Breakthrough in brain stimulation offers cautious hope for depression - Harvard Health - October 21st, 2022 [October 21st, 2022]
- Life-changing treatment program in Ohio expanding for veterans and first responders - WTRF - October 19th, 2022 [October 19th, 2022]
- Over 60% Of Pokemon Fans Are Most Excited For This Feature In Scarlet & Violet - SVG - October 19th, 2022 [October 19th, 2022]
- Radaro and NorthStar Digital Solutions partner to solve industry-wide process gaps in LTL & TL transportation - PR Newswire - October 19th, 2022 [October 19th, 2022]
- Avalanche Technology and TMS-Elektronik Announce Representation Agreement for the Republic of Turkey - PR Web - October 17th, 2022 [October 17th, 2022]
- Global Talent Management Software (TMS) Market Report 2022: A $25+ Billion Market by 2027 - Industry Trends, Share, Size, Growth, Opportunities and... - October 17th, 2022 [October 17th, 2022]
- A Foreword to Adam Smith's The Theory of Moral Sentiments - Independent Institute - October 17th, 2022 [October 17th, 2022]
- Deutsche Telekom to buy 100% electric company cars from 2023 - www.electrive.com - October 17th, 2022 [October 17th, 2022]
- What Happens in the Brain During Transcranial Magnetic Stimulation? - Technology Networks - October 13th, 2022 [October 13th, 2022]
- TMS and SIS to vie for soccer championship - Saipan Tribune - October 13th, 2022 [October 13th, 2022]
- Soterix Medical Announces award of Fast Track NIH grant to develop a Parcel-Guided software to improve efficacy of rTMS treatment for Depression - PR... - October 13th, 2022 [October 13th, 2022]
- Interview: Kindra Neely Talks Healing Through Art and Personal Hope in 'Numb to This' - The Mary Sue - October 13th, 2022 [October 13th, 2022]
- Local veteran finds success with TMS therapy | Local News | thenewsenterprise.com - Elizabethtown News Enterprise - September 29th, 2022 [September 29th, 2022]
- Racin' Today Everything's Big In Texas Including Criticism Of TMS - RacinToday.com - September 29th, 2022 [September 29th, 2022]
- Start over from scratch: Race weekend at TMS stirs up track reconfiguration rumors - The Dallas Morning News - September 29th, 2022 [September 29th, 2022]
- $28 Billion Transportation Management System Markets - Global Forecast to 2027: Increasing Demand for TMS to Tackle High Demand from e-Commerce -... - September 29th, 2022 [September 29th, 2022]
- EDAP TMS Hosting Urology Expert Panel and Live Focal One Technology Demonstration - GlobeNewswire - September 29th, 2022 [September 29th, 2022]
- Reddick prevails in wild race that sees record number of yellow flags at TMS - Denton Record Chronicle - September 29th, 2022 [September 29th, 2022]
- e2log and Wipro Discuss How Technology Accelerates Logistics Engines That Drive Global Supply Chains at Gartner Supply Chain Symposium/Xpo 2022 EMEA -... - September 29th, 2022 [September 29th, 2022]
- Transcranial Magnetic Stimulators Market Size And Forecast To 2022 |eNeura BrainsWay Ltd., MagVenture, Nexstim Plc, TMS Neuro Solutions, Magstim The... - September 29th, 2022 [September 29th, 2022]